Natixis Advisors L.P. Has $6.21 Million Stake in Catalent Inc (NYSE:CTLT)
Natixis Advisors L.P. decreased its position in Catalent Inc (NYSE:CTLT) by 2.0% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 114,513 shares of the company’s stock after selling 2,306 shares during the quarter. Natixis Advisors L.P. owned about 0.08% of Catalent worth $6,207,000 as of its most recent filing with the SEC.
A number of other hedge funds have also bought and sold shares of the business. Dimensional Fund Advisors LP raised its holdings in Catalent by 4.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,326,230 shares of the company’s stock valued at $41,351,000 after buying an additional 55,260 shares in the last quarter. Geode Capital Management LLC boosted its position in Catalent by 8.2% during the fourth quarter. Geode Capital Management LLC now owns 1,422,860 shares of the company’s stock worth $44,364,000 after purchasing an additional 108,407 shares during the period. Los Angeles Capital Management & Equity Research Inc. bought a new stake in Catalent during the first quarter worth approximately $214,000. State Board of Administration of Florida Retirement System boosted its position in Catalent by 16.4% during the first quarter. State Board of Administration of Florida Retirement System now owns 190,430 shares of the company’s stock worth $7,730,000 after purchasing an additional 26,844 shares during the period. Finally, California Public Employees Retirement System grew its holdings in Catalent by 13.5% during the first quarter. California Public Employees Retirement System now owns 196,415 shares of the company’s stock valued at $7,972,000 after purchasing an additional 23,335 shares during the last quarter.
A number of research firms have recently commented on CTLT. Jefferies Financial Group raised shares of Catalent from a “hold” rating to a “buy” rating and lifted their price target for the company from $50.00 to $62.00 in a research report on Friday, June 21st. UBS Group upped their price objective on shares of Catalent to $64.00 and gave the stock a “buy” rating in a report on Tuesday, July 23rd. Zacks Investment Research lowered shares of Catalent from a “buy” rating to a “hold” rating in a research note on Thursday, September 5th. Morgan Stanley lifted their target price on shares of Catalent from $50.00 to $61.00 and gave the stock an “overweight” rating in a report on Wednesday, August 28th. Finally, Robert W. Baird boosted their target price on shares of Catalent from $50.00 to $60.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 28th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $57.14.
Catalent (NYSE:CTLT) last issued its quarterly earnings results on Tuesday, August 27th. The company reported $0.65 EPS for the quarter, topping analysts’ consensus estimates of $0.62 by $0.03. Catalent had a return on equity of 15.89% and a net margin of 5.46%. The company had revenue of $725.70 million during the quarter, compared to analyst estimates of $719.20 million. During the same period in the previous year, the company earned $0.67 earnings per share. The company’s quarterly revenue was up 5.9% compared to the same quarter last year. Sell-side analysts expect that Catalent Inc will post 1.81 earnings per share for the current year.
In other Catalent news, SVP Steven L. Fasman sold 4,053 shares of the company’s stock in a transaction that occurred on Thursday, July 11th. The stock was sold at an average price of $54.04, for a total value of $219,024.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Gregory T. Lucier acquired 2,000 shares of Catalent stock in a transaction on Monday, September 9th. The stock was purchased at an average price of $51.64 per share, with a total value of $103,280.00. The disclosure for this purchase can be found here. 1.40% of the stock is owned by corporate insiders.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Further Reading: Rule of 72
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.